Androgen Ablation With or Without Docetaxel in Treating Patients With Advanced Prostate Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen ablation therapy
may lessen the amount of androgens made by the body. Drugs used in chemotherapy, such as
docetaxel, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. It is not yet known whether giving androgen ablation
therapy together with docetaxel is more effective than giving androgen ablation therapy alone
in treating patients with advanced prostate cancer.
PURPOSE: This randomized phase III trial is studying androgen ablation and docetaxel to see
how well they work compared with androgen ablation alone in treating patients with advanced
prostate cancer.